BetterLife Pharma Inc. Files July 2024 6-K Report

Ticker: BETRF · Form: 6-K · Filed: Jul 15, 2024 · CIK: 1464165

Sentiment: neutral

Topics: reporting, sec-filing, foreign-private-issuer

Related Tickers: BETRF

TL;DR

BetterLife Pharma (BETRF) filed its July 6-K, standard reporting for investors.

AI Summary

BetterLife Pharma Inc. filed a Form 6-K on July 15, 2024, reporting for the month of July 2024. The company, formerly known as Pivot Pharmaceuticals Inc. and Neurokine Pharmaceuticals Inc., is incorporated in A1 and has its principal executive office in Vancouver, BC. This filing is made under the 1934 Securities Exchange Act.

Why It Matters

This filing provides routine updates and disclosures for BetterLife Pharma Inc., which is important for investors to stay informed about the company's ongoing reporting obligations.

Risk Assessment

Risk Level: low — This filing is a routine report and does not contain significant new financial or operational information that would inherently increase risk.

Key Players & Entities

FAQ

What is the purpose of a Form 6-K filing?

A Form 6-K is a report of foreign private issuers pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934, used to provide information that the company makes or is required to make public in its home country, files or is required to file with a stock exchange, or distributes or is required to distribute to its security holders.

When was BetterLife Pharma Inc. formerly known as Pivot Pharmaceuticals Inc.?

The date of the name change from Pivot Pharmaceuticals Inc. to BetterLife Pharma Inc. was April 17, 2015.

What is BetterLife Pharma Inc.'s fiscal year end?

BetterLife Pharma Inc.'s fiscal year ends on January 31.

What is the SIC code for BetterLife Pharma Inc.?

The Standard Industrial Classification (SIC) code for BetterLife Pharma Inc. is 2834, which corresponds to Pharmaceutical Preparations.

Does BetterLife Pharma Inc. file annual reports under Form 20-F or 40-F?

BetterLife Pharma Inc. indicates that it files annual reports under cover of Form 20-F.

Filing Stats: 344 words · 1 min read · ~1 pages · Grade level 14.8 · Accepted 2024-07-15 16:30:15

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934 , the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BETTERLIFE PHARMA INC. Date: July 15, 2024 By: /s/ Moira Ong Name: Moira Ong Title: Chief Financial Officer 3

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing